Service mix

Injectables vs devices: run the economics before you sign anything

By Dr Zlata Dancova & Lucia O'BrienOctober 27, 20268 min read

At some point every aesthetic clinic owner sits across from a device rep with a glossy brochure, a financing plan, and a projection slide where the machine pays for itself by spring. This article is the worksheet we wish someone had handed us before that meeting.

Two different businesses in one room

Injectables and devices feel like neighbouring items on a treatment menu. Financially they are different species.

Injectables are a consumables business. Your cost walks in the door inside a box, you pay for it roughly as you use it, and capacity scales with clinical hours. Margins live in pricing, protocol, and retention. The risk is clinical skill and product cost creep, not capital.

A device is a capital business. You pay most of the cost up front, before the first patient, and then race to amortize it against treatments whose demand you are usually guessing. Margins live in utilization. The risk is an expensive machine standing in a room, switched off, while the loan payment arrives monthly with perfect reliability.

Neither is better. But they reward different clinics at different stages, and the brochure never mentions that.

The six numbers to run

Before signing for any device, put real values on these six lines. All figures below are illustrative placeholders; the discipline is in running your own.

• True all-in cost. Purchase price plus consumables per treatment, service contract, training, marketing launch, and the applicator or tip replacements the rep mentions quietly. The sticker is rarely more than two thirds of the five-year cost.
• Honest utilization. Not "treatments possible per day" but treatments you will actually sell per week, estimated from your current patient list, not from the rep's national averages. If you cannot name twenty existing patients who would book it, the number is a wish.
• Payback period at that honest utilization. If payback only works at optimistic volume, the machine owns you, not the reverse.
• Margin per treatment-room hour. A room running injectables at strong margin per hour sets the benchmark. The device must beat the benchmark, or free up capacity that does, otherwise it is just a more photogenic way to earn less from the same square meters.
• Operator dependence. Who can run it, what happens when she leaves, and how long training a replacement takes. A device that only one person can operate is a single point of failure financed over five years.
• Trend half-life. Injectables demand has proven durable for decades. Device categories rise and fall faster, and a five-year loan on a three-year trend is a specific kind of regret.

The waitlist test

The cleanest de-risking tool costs nothing: sell it before you buy it. Announce the treatment to your existing patients as "coming soon", open a deposit-free waitlist, and watch the real number. A waitlist of forty names justifies the meeting with the rep. A waitlist of six answers the question too, for the price of one Instagram post instead of five figures of capital.

This is the same demand-first ordering we apply to everything in revenue growth: proven demand first, capacity second. Clinics that buy capacity hoping demand follows are financing hope.

How we sequenced it

At SK Clinic, the growth from $140k to seven figures in 18 months was carried overwhelmingly by practitioner-led treatments: injectables and skin work with consumable economics, high repeatability, and no capital anchor. Devices entered later, selectively, only where a waitlist had already proven the demand and the margin per room hour beat what the room was already earning.

That ordering was not caution for its own sake. Early-stage clinic capital has a better home: the systems that convert and keep patients. A review engine, a working inquiry process, and a trained front desk, which we described in the marketing system and the CRM piece, outperformed any machine we could have bought in year one, at a fraction of the cost.

Buy demand creation before you buy capacity. Machines cannot answer inquiries.

When the device is right

To be clear, devices earn their place: when the waitlist is real, the payback math survives honest utilization, more than one operator is trained, the service contract is in the spreadsheet, and the treatment deepens your position instead of diluting it. A clinic known for natural results does not need the machine every competitor bought last year. It needs the one its own patients are already asking for.

The full service-mix chapters in the guide include the worksheet version of this framework, the waitlist playbook, and the pricing logic we used for both categories.